NASDAQ
01.04.26 | 21:03
4,880 US-Dollar
+2,09 % +0,100
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 17.03. | Citizens reiterates Foghorn Therapeutics stock rating on pipeline progress | 3 | Investing.com | ||
| 12.03. | Foghorn Therapeutics: Jefferies bekräftigt "Buy"-Rating im Vorfeld von Pipeline-Daten | 1 | Investing.com Deutsch | ||
| 12.03. | Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data | 2 | Investing.com | ||
| 12.03. | Stifel reiterates Foghorn Therapeutics stock rating at buy | 2 | Investing.com | ||
| FOGHORN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 11.03. | Foghorn Therapeutics GAAP EPS of -$1.18 misses by $0.08, revenue of $30.91M misses by $0.31M | 1 | Seeking Alpha | ||
| 11.03. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook | 111 | GlobeNewswire (Europe) | FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential... ► Artikel lesen | |
| 23.02. | Foghorn Therapeutics appoints Ryan Maynard as CFO | 1 | Seeking Alpha | ||
| 23.02. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer | 144 | GlobeNewswire (Europe) | WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| 23.02. | Foghorn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.02. | Jefferies stuft Foghorn Therapeutics mit "Buy" ein und sieht erhebliches Potenzial | 2 | Investing.com Deutsch | ||
| 17.02. | Jefferies initiates Foghorn Therapeutics stock with buy rating | 13 | Investing.com | ||
| 13.01. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium | 200 | GlobeNewswire (Europe) | WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases... ► Artikel lesen | |
| 13.01. | Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26 | 3 | Investing.com | ||
| 12.01. | Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target | 2 | Investing.com | ||
| 12.01. | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.01. | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 | 531 | GlobeNewswire (Europe) | Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13th, 2026 Phase... ► Artikel lesen | |
| 18.12.25 | BTIG stuft Foghorn Therapeutics mit "Buy" ein - Potenzial in der Krebs-Pipeline | 2 | Investing.com Deutsch | ||
| 18.12.25 | BTIG initiates Foghorn Therapeutics stock with Buy rating on cancer pipeline | 1 | Investing.com | ||
| 04.12.25 | Foghorn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | Stifel initiates Foghorn Therapeutics stock with Buy rating, $12 target | 1 | Investing.com |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CYCLERION THERAPEUTICS | 6,310 | 0,00 % | Morning Market Movers: Cyclerion Therapeutics, Binah Capital Group, Target Hospitality Corp., nCino See Big Swings | WASHINGTON COUNTY (dpa-AFX) - At 8:20 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before... ► Artikel lesen | |
| QIAGEN | 34,900 | +0,72 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 17,170 | +4,38 % | Jefferies lowers Monte Rosa stock price target to $30 on valuation | ||
| COGENT BIOSCIENCES | 35,240 | -8,44 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| MAZE THERAPEUTICS | 29,050 | -2,45 % | Zifo Technologies: Zifo and Maze Therapeutics Partner to Power Precision Medicine | SAN FRANCISCO, Feb. 18, 2026 /PRNewswire/ -- Zifo, the leading global enabler of AI and data-driven enterprise informatics for science driven organizations and Maze Therapeutics Inc have... ► Artikel lesen | |
| AKTIS ONCOLOGY | 17,070 | -4,58 % | Aktis Oncology Inc.: Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results | Progressing vision to expand the reach of targeted radiopharmaceuticals to large patient populationsAnticipating multiple milestones in the next 12 months, including initiation of Phase 1b clinical... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 14,350 | +3,24 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| ARCELLX | 114,74 | -0,07 % | Gilead extends Arcellx tender offer deadline to April 24 | ||
| NUVALENT | 105,63 | +3,11 % | Stifel reiterates Buy rating on Nuvalent stock ahead of ROS1 launch | ||
| STRUCTURE THERAPEUTICS | 50,20 | 0,00 % | What's Going On With Structure Therapeutics Stock On Wednesday? | ||
| BIONTECH | 77,30 | +4,04 % | JETZT über 50 % KURSPOTENZIAL!? BioNTech, TUI und Bayer-Partner MustGrow | Lust auf ein Investment in einen Geheimtipp mit riesigem Marktpotenzial? Dann ist die Aktie von MustGrow interessant. Das Unternehmen wird mit unter 40 Mio. CAD bewertet. Die biologischen und regenerativen... ► Artikel lesen | |
| EVOTEC | 4,457 | +2,93 % | Evotec streicht 800 Stellen - und trotzdem sehen Analysten 100% Kurspotenzial | 800 Stellen weg, Kosten explodiert, Gewinne verschoben - Evotec steckt tief in der Krise. Doch Analysten sehen mehr als 100% Kurspotenzial. Was steckt hinter dem Widerspruch? Rund 800 Stellen werden... ► Artikel lesen | |
| CULLINAN THERAPEUTICS | 13,940 | -1,76 % | Cullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Data readouts planned for CLN-978 across all three autoimmune indications in 2026, including single dose and repeat dosing data Company to complete monotherapy expansion cohorts to determine recommended... ► Artikel lesen | |
| ERASCA | 16,605 | +2,98 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 319,21 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs | FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous... ► Artikel lesen |
Das Unternehmen FOGHORN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,100 (+2,09 %) liegt der Kurs bei 4,880 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FOGHORN THERAPEUTICS INC finden Sie auf Wallstreet Online.